Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924 - Test2 - elhamkhani - TriplyDB

Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924

Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924

http://www.wikidata.org/entity/Q30410498

about

Cellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancer Ubiquitylation, neddylation and the DNA damage response Chemogenomic Study of Carboplatin in Saccharomyces cerevisiae: Inhibition of the NEDDylation Process Overcomes Cellular Resistance Mediated by HuR and Cullin Proteins Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway.Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems.ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Targeting cullin-RING ligases for cancer treatment: rationales, advances and therapeutic implications.Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine Inactivating UBE2M impacts the DNA damage response and genome integrity involving multiple cullin ligases.It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer.MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.Suppression of tumor angiogenesis by targeting the protein neddylation pathway.MLN4924 therapy as a novel approach in cancer treatment modalities.Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors.Pevonedistat, a first-in-class NEDD8-activating enzyme (NAE) inhibitor, combined with azacitidine, in patients with AML.MLN4924 neddylation inhibitor promotes cell death in paclitaxel-resistant human lung adenocarcinoma cells.Neddylation inhibitor MLN4924 induces G2 cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin.Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.Regulation of Mammalian DNA Replication via the Ubiquitin-Proteasome System.

P2860

Q26796258-E0806849-6457-41B1-BCD3-9E856C752E1E Q28087342-DBF30DCD-576E-4089-81DD-3551FCEB95DA Q28551657-DEB6A5D7-8BED-45D2-B434-4F781D9174EE Q30276526-57841381-7676-4EC9-B1FF-506D2E247918 Q30371587-F4FD5C09-F530-49FD-8311-80DD9DAB558F Q33641924-11A50138-8105-4A72-8F5E-ED20AB01D31D Q33648465-48C4E630-3F9F-4872-95F6-959DDE9B1A3F Q33983255-754903CB-B854-4838-BCAC-AA93EFBFE9EF Q34043821-2E4C6696-3731-464F-B493-B5141CE902F8 Q34543264-EC91AFFB-9132-4C4D-A476-F642FA286949 Q34563129-F68BF18B-AD56-4F9B-B6D3-01C84E994FD2 Q34978486-F4FDF405-0156-4B90-B2F0-1C1B73A6CCF9 Q34979606-6809043F-E75A-4E07-9A5D-972A7CD46D92 Q35207086-E1752B65-9DA8-4B59-A069-70896575060B Q35678132-2ABF0DBC-FDB0-4083-BEBE-CD5796862E51 Q35832285-CD717460-458C-4EEF-9A60-1928528A4C9B Q36305476-467A6B27-5224-4D9B-BE2A-8317096986AB Q36876973-7C0CACFD-2F60-4908-92BC-ABB0C5CEF671 Q37620640-F8D78F6F-E681-467B-B615-1EFA473F44E7 Q38570362-45EB1597-C53F-4A41-B142-415AB3E96739 Q38704026-31CF3BE5-1CB9-4285-8E8C-2C59555B4E7B Q38736706-700CED92-7C06-4620-9CEE-2D8C3784E476 Q40071281-64367760-70C4-47CF-99A8-958B3AD0FB11 Q48216923-31A4AAD4-EDE4-4432-822E-AE75EAFE6D5F Q48517497-226C4DC2-9E7A-492A-8E04-206975BA6C81 Q49456490-26E3BE6C-B486-4C23-B84F-E71B6583B0A8 Q52584568-FFE00910-252C-4CB5-AF55-549CFF47670E Q55239552-81E7289B-AF46-46A0-898F-A351CDB54529

P2860

Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924

http://www.wikidata.org/entity/Q30410498

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Overcoming platinum resistance ...... neddylation inhibitor MLN4924

@ast

Overcoming platinum resistance ...... neddylation inhibitor MLN4924

@en

type

label

Overcoming platinum resistance ...... neddylation inhibitor MLN4924

@ast

Overcoming platinum resistance ...... neddylation inhibitor MLN4924

@en

prefLabel

Overcoming platinum resistance ...... neddylation inhibitor MLN4924

@ast

Overcoming platinum resistance ...... neddylation inhibitor MLN4924

@en

P1433

Q30410498-7683AB10-7700-4DBD-9591-201F43174968

P1476

Q30410498-32644ECF-5492-4293-9703-3F8EBD26C3B2

P2093

Q30410498-34520D3F-371C-412E-85F6-6D45EC198094

Q30410498-3A7B1934-7D28-4940-B016-39452D95C20D

Q30410498-4886FDBB-8922-4736-852F-89FD033E870C

Q30410498-7C7F29FF-7514-47F8-A254-1F4AC81243F8

Q30410498-81DC8A0C-2441-4C97-A969-171B37E732AF

Q30410498-D3AA214A-131F-4B80-9437-34C64195DD18

Q30410498-E49AFAFA-79D4-42BD-B611-4DAA21E32F0F

Q30410498-F92D6E9C-42C5-4162-A933-4DC84DC7075B

P2860

Q30410498-12EEC21D-10C7-48C7-BC80-0276B3C469A9

Q30410498-13E6D3A8-67F6-4DC2-9697-9237BC1706DB

Q30410498-1917B5E8-AD85-4B6F-A958-43008D43C85E

Q30410498-349D342B-A565-4B6D-B6C3-EF5773789DC9

Q30410498-3727E9B2-A082-4E0A-8966-F6B2E8915585

Q30410498-3C1C4B65-F3E7-4D64-B260-52E74F5C7F1E

Q30410498-3E06269A-E324-46D3-A844-7B1B96D8F329

Q30410498-51C96016-575C-4DC0-91A6-BC7393500D17

Q30410498-53F0B52B-B3D2-474A-A5B7-604126F4CAB3

Q30410498-64215D4A-CC16-4A8A-A6A8-576A9A15C39E

P304

Q30410498-92854706-CF80-442C-A117-E8B76F664124

P31

Q30410498-71FB121B-0F2B-496E-9DB1-D83498C835DC

P356

Q30410498-75517B77-0634-45CC-A080-AD690B343CB9

P433

Q30410498-913EE111-C2FE-479C-8EA3-D2308012CE17

P478

Q30410498-49404FFE-5E51-4DB1-9435-AA417988BD16

P50

Q30410498-20C422AA-B620-467F-9571-21EAEBB3D57A

Q30410498-55DD83B9-5F88-435D-B217-A750FD9AF93A

P577

Q30410498-1B43529A-6DA4-425E-AA6E-063A285E94FC

P698

Q30410498-DA4438DC-41C9-4B18-83B3-86A6580989D8

P921

Q30410498-601AA1F8-502E-401F-BD7E-B5BFCF516CCD

P932

Q30410498-52C3C142-1DF1-40E9-A230-26BBAF095566

P356

1535-7163.MCT-12-1028

P1433

Molecular Cancer Therapeutics

P1476

Overcoming platinum resistance ...... neddylation inhibitor MLN4924

@en

P2093

Allison J Berger

http://www.w3.org/2001/XMLSchema#string

Amir A Jazaeri

http://www.w3.org/2001/XMLSchema#string

Jennifer L Bryant

http://www.w3.org/2001/XMLSchema#string

Jonghoon Park

http://www.w3.org/2001/XMLSchema#string

Mark R Conaway

http://www.w3.org/2001/XMLSchema#string

Michael A Milhollen

http://www.w3.org/2001/XMLSchema#string

Peter G Smith

http://www.w3.org/2001/XMLSchema#string

Susan C Modesitt

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway

E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification

Cancer statistics, 2012

Clear cell carcinoma of the ovary: a review of the literature

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Drug combination studies and their synergy quantification using the Chou-Talalay method

Cellular processing of platinum anticancer drugs

NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells

Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.

P304

1958-1967

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-12-1028

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23939375

http://www.w3.org/2001/XMLSchema#string

P921

P932

3795967

http://www.w3.org/2001/XMLSchema#string